We may also use third-party cookies that help us analyze and understand how you use this website. These cookies are optional and can be disabled via the 'Non-Essential' toggle below.
After opting out, cookies that were already loaded will remain but the code reading them will not be loaded. Please note that opting out of some of these cookies may impact your browsing experience.
Essential cookies help the website function by enabling functionality and remembering user choices. The website will not function properly without them.
|pint-checkbox-non-necessary||livingwithglaucoma.com||Remembers your selected cookie consent preference||3 months|
|pint-cookies-accepted||livingwithglaucoma.com||Remembers that you have made a cookie preference||1 Year|
Non-Essential cookies are those that help compile site statistics or are provided by third-party services, like ad networks, real-time support chat, or videos.
|_fbp||livingwithglaucoma.com||Analytics uses this to automatically save a unique identifier for your session||3 months|
|_ga||livingwithglaucoma.com||Analytics uses this as a top-level variable||1 month|
|_gcl_au||livingwithglaucoma.com||Analytics uses this as a conversion linker||3 days|
|_gat||livingwithglaucoma.com||Analytics uses this as a rate limiter and does not store data||1 minute|
|_gid||livingwithglaucoma.com||Analytics uses this to count page views||1 day|
INDICATION FOR USE
The iStent inject® W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild-to-moderate primary open-angle glaucoma.
The iStent inject® W is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.
Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard.
The iStent inject® W is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.
The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure (IOP). The safety and effectiveness of the iStent inject® W have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated intraocular pressure (IOP) > 24 mmHg or unmedicated intraocular pressure (IOP) < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents.
Common postoperative adverse events reported in the iStent inject® randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject® vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%).
Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.